Efficacy of COVID-19 Vaccination in People Living with HIV/AIDS in a Northern Brazil: Cross-Sectional Study

The evaluation of the efficacy of COVID-19 vaccination in immunocompromised individuals, such as people living with HIV/AIDS (PLWH), still is of great global importance. The present study aimed to describe the presence of anti-SARS-CoV-2 IgG antibodies in PLWH vaccinated and unvaccinated against COVID-19 in the city of Belém, northern Brazil.

A cross-sectional study involving 510 PLWH was conducted from December 2021 to May 2022. Participants answered a sociodemographic questionnaire and subsequently underwent an anti-SARS-CoV-2 enzyme immunoassay for the detection of IgG antibodies, as well as quantification of CD4+ T lymphocytes and HIV-1 plasma viral load.

Most participants were male (70%), aged 25-50 years (72%), single (71.4%), and low-income (50.4%). The prevalence of anti-SARS-CoV-2 IgG antibodies was 94.3% (481/510), with most vaccinated individuals having received at least two doses of a COVID-19 vaccine. An association was observed between antibody levels and the number of vaccine doses, CD4+ T lymphocyte count, CD4+/CD8+ T lymphocyte ratio, and HIV-1 viral load.

PLWH developed high levels of antibodies against SARS-CoV-2 after receiving the vaccine, demonstrating that COVID-19 vaccination is of fundamental importance for the protection against severe COVID-19 in this specific group of immunocompromised individuals.